Tilman Schneider-Hohendorf

List of Publications by Year
in descending order

45 papers	2,075 citations	236833 25 h-index	233338 45 g-index
47 all docs	47 docs citations	47 times ranked	3555 citing authors

#	Article	IF	Citations
1	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2973-82.	3.3	157
2	l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology, 2013, 81, 865-871.	1.5	140
3	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. Journal of Experimental Medicine, 2014, 211, 1833-1846.	4.2	134
4	$CD4^+$ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology, 2016, 18, 807-818.	0.6	129
5	Natalizumab-associated PML. Neurology, 2017, 88, 1197-1205.	1.5	102
6	Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Annals of Neurology, 2014, 75, 739-758.	2.8	100
7	CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nature Communications, 2016, 7, 11153.	5.8	98
8	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Science Translational Medicine, 2019, 11, .	5.8	92
9	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	5.8	87
10	Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. Journal of Autoimmunity, 2011, 36, 106-114.	3.0	77
11	Effects on capacitance by overexpression of membrane proteins. Biochemical and Biophysical Research Communications, 2008, 369, 1022-1026.	1.0	75
12	Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e195.	3.1	66
13	PML risk stratification using anti-JCV antibody index and L-selectin. Multiple Sclerosis Journal, 2016, 22, 1048-1060.	1.4	62
14	Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. European Journal of Immunology, 2010, 40, 3581-3590.	1.6	56
15	Sex bias in MHC I-associated shaping of the adaptive immune system. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2168-2173.	3.3	51
16	Therapeutic uses of anti-Î±4-integrin (anti-VLA-4) antibodies in multiple sclerosis. International Immunology, 2015, 27, 47-53.	1.8	50
17	Immunological and clinical consequences of treating a patient with natalizumab. Multiple Sclerosis Journal, 2012, 18, 335-344.	1.4	40
18	Neurocognitive decline in HIV patients is associated with ongoing Tâ€cell activation in the cerebrospinal fluid. Annals of Clinical and Translational Neurology, 2015, 2, 906-919.	1.7	40

#	Article	IF	Citations
19	Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 271-276.	3.3	40
20	Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2036-2044.	1.4	39
21	Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain, 2019, 142, 3411-3427.	3.7	39
22	Ineffective treatment of PML with pembrolizumab. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e627.	3.1	39
23	Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus. Journal of Neuroinflammation, 2018, 15, 236.	3.1	38
24	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
25	Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. Multiple Sclerosis Journal, 2018, 24, 563-573.	1.4	28
26	Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study. Frontiers in Immunology, 2018, 9, 1560.	2.2	24
27	Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain, 2022, 145, 1711-1725.	3.7	23
28	Classification of neurological diseases using multi-dimensional CSF analysis. Brain, 2021, 144, 2625-2634.	3.7	22
29	Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. Multiple Sclerosis Journal, 2018, 24, 1871-1882.	1.4	21
30	Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis. PLoS ONE, 2010, 5, e15478.	1.1	21
31	Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. Aids, 2014, 28, 793-795.	1.0	20
32	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494.	1.5	18
33	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC Neurology, 2019, 19, 190.	0.8	17
34	VLA-2 blockade *in vivo* by vatelizumab induces CD4+FoxP3+ regulatory T cells. International Immunology, 2019, 31, 407-412.	1.8	14
35	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. Brain, 2021, 144, 3126-3141.	3.7	14
36	Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2019, 93, 550-554.	1.5	13

#	ARTICLE	IF	CITATIONS
37	MCAM/CD146 Signaling via PLCÎ³1 Leads to Activation of Î²1-Integrins in Memory T-Cells Resulting in Increased Brain Infiltration. Frontiers in Immunology, 2020, 11, 599936.	2.2	9
38	Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). BMC Neurology, 2015, 15, 96.	0.8	7
39	CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology, 2016, 87, 958-959.	1.5	7
40	Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia. JMM Case Reports, 2016, 3, e005053.	1.3	7
41	Nitazoxanide May Modify the Course of Progressive Multifocal Leukoencephalopathy. Journal of Clinical Immunology, 2018, 38, 4-6.	2.0	5
42	High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients. Multiple Sclerosis Journal, 2021, 27, 1491-1496.	1.4	5
43	Trafficking of lymphocytes into the CNS. Oncotarget, 2015, 6, 17863-17864.	0.8	5
44	Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier. Journal of Visualized Experiments, 2017, , .	0.2	3
45	Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2020, 95, 505-505.	1.5	1